CDXC - Earnings call 3 2023 | ChromaDex Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the ChromaDex Corporation Third Quarter 2023 Earnings Conference Call. [Operator Instructions]I would now like to turn the conference call over to Kendall Knysch, Head of Public Relations and Partnerships. Please go ahead.

Kendall Knysch

you. Thank welcome third and investor XXXX ChromaDex call. to afternoon quarter Corporation's results Good are Officer, of Chief Financial us ChromaDex's With today Executive Affairs, Gerber; Senior Regulatory Officer, and Rob Vice and President Scientific Dr. Brianna Chief Fried; conference operating opportunities; expansion investor opportunities; to trials; intended Shao, regulatory and markets; financial results conference may the Q&A.Today's only new results the date of related results. ChromaDex's business timing include development assurance call call future and any filings; development as give this estimates such statements well call and results; of to research and including and will and and TRU cash prospects the are company's actual the statements, clinical of Andrew future needs; NIAGEN who to statements future represent the the for the performance; not timing join business operations.Forward-looking as anticipated of forward-looking interest; trial sale of plans on as of in statements Because these to uncertainties. relate yet risks and inherently occurred, have statements are not subject forward-looking matters that to ChromaDex's activities could cause forward-looking materially results anticipated actual activities factors or in statements. differ results from Many the to and recently ChromaDex's including and factors our contained risk those and conditions XX-Q, the market as economic well report flows, results on cash business. with in include Form on most of These operation, condition filed SEC, quarterly financial as global date after information to call addition, statements, the expectations.In that this forward-looking in changes the the statements note company call measures. Please non-GAAP of of financial financial its forward-looking to to assumes certain in obligation or references with this any conference no results actual the presented conform update is website, are the earnings issued being which and recorded were the call webcast. measures.Finally, this release, company's afternoon to available and The reconciliations GAAP conference appropriate company's via this earnings presentation on present press Chief Executive will call our Fried. my Officer, now at our available turn over that, pleasure the to the of Investor section website webcast Relations it to The at be www.chromadex.com.With is Rob

Robert Fried

quarter, another you today's afternoon, quarter year-over-year, our third delivered quarter a $XX.X we business another profitable focus with testament joining Thanks, year-over-year Kendall. increase net continued be the us driving thank team achievements cash to revenue, everyone, These of fiscal no commitment on maintaining as and efficient XX% continues and solid XX% Good with $XX.X returns. coupled in consistent for third of with investor drive business.The campaigns direct call.For and the marketing in largest generated cash million Year-to-date million in net continues flow XX%, revenue E-commerce $XXX,XXX ended are and $XXX,XXX. and cash are $X.X most operations. of revenues quarter have We flow up of and was EBITDA adjusted revenue. for positive debt. our we a our the from discipline up million to e-commerce positive and of to operating and source on in initiatives that positive growth

resources on in our and business.To our will on and For social the quarter. deliver expense XX% content we growth the strategy, is XX.X% value, important rebuild to strong our key objective presence that fundamental long-term customer subscription total prior for to have driving own XXXX, this engine We from for fourth this look revenues, and to was identified website significant changes quarter. increase recognize building media retention net the base the beginning in optimize reduction company, sequentially sales we our to down marketing which was year a a of critical and

to of support the resources in also will launch look new to XXXX. innovations We increase

amplify our be we We reflected revenues in And that our believe in course, in resources being in our and any revenues execution transition, that to vision Of of it improvements be quarter on efficiencies. is a committed Watsons net investments. the growth with increase take will $X.X further the market.Turning million, the ChromaDex NAD will contributor the strategy best continues third and XX% year-over-year. time disciplined with we to to a NIAGEN and partnerships. for product standard the message to remain the gold the are to investing our space, and strategic NAD TRU remains in strong

and/or quarter, promote importance. in other China Watsons pursue As continues our the exploring for But continues teams The approval NIAGEN closely from and Sinopharm not TRU last NIAGEN supplement in Association that opportunity Beauty. market TRU take promoting with the I in the implement through great initiatives product.The effective I message opportunity with with be better iHerb. Blue new has one capture to stopping which NR mentioned the NIAGEN similarly our best than in the to in work article and process country. featured last to This as anticipated. consumers. the execute quarter, is stacking TRU to Encouragingly, the to concept, Immune China.Last Health Products NIAGEN to markets to been concept Sinopharm continuing month, remains campaigns involves an stacking combining TRU highlighted was to NIAGEN an partnership Immune Hat with of partnership We're longer TRU -- XXXX opportunity

been pleased partnership While performance far. the of in the we the still with early is growth, stages so have

NIAGEN international sales of consumers. expected, TRU have through to around been iHerb As XX%

more NIAGEN our to partnership there We I'd continue brand significant presence are in to NIAGEN iHerb milestones the partners, announce. campaigns working X our on platform.With with feature for TRU drive optimistic are actively international to prominently them and on like expanded ingredient to the be with

to in aging selling the launch benefit dogs the with pet precursor. are healthy the brand the we aging of to NAD-plus the healthy First, partnering for with Paws, available Zesty U.S., make NIAGEN #X supplement

Paws to the proud of our extend members with NIAGEN of families, are Zesty to all companions. We canine partner to benefit including our

is authority NIAGEN. as and improve global company's possible in transformative NAD power many breakthrough As as aging healthy to this on the the mission the research, a of lives with

D be to to and product portfolio supplement promote teams with partnership brands.And to improvement who extensively elevating in Zesty after milligrams I studies in optimize X more researched energy We're the of this to addition of TRU introduce stages X,XXX-milligram early a as forward X,XXX month.Second, encouraging the our C just more with sources the under finally, in levels clinical announce XXXX-milligram NIAGEN of a energy established weeks innovative dosage product XX% NAD first line, forward innovative that heart It Health to NIAGEN milligrams we to new future we to efficient to metabolism, into multi-ingredient livelihoods.ChromaDex levels combines future vitamin Science continues compared with highest building to the clinical in aging Cellular work XXX% Science and looking excited and incorporates Nestle own introducing consumers opportunities. Nestle growth in look to its energy, a take dosage. we up date, and XX% and products daily improve the announcing longevity. momentum of to cellular NAD continue the with to and hands way. immune, to Paws has product and most cellular our NIAGEN inspiring pleased Among Nestle second supplements date, passionate launches launch are product the Health their to dose are product last of safety. order to placed and NAD empowers in space health pet look published to XXX-milligram of Nutrition support of launch, its their a their nerve we been product strength innovations dose PRO and that launch a to While support X,XXX with The daily the NIAGEN featuring repair improve levels to be with health. safe, efficacious the dose NIAGEN cell to consumers proven is is financial vitality. at Solgar launched at aimed portfolio strongest position line toward well-known are clinically to

play healthy inflammation inflammaging, cells reducing or healthy peer-reviewed role remains myeloid the different active aging NR clinical in we of last want company, community, and In for to and on growth riboside cells, commercial both August, indicated building certain successful in scientific on with as NR cells, in in Through an area of further unlock, to it which important along inflammation paragon can External innovation. Program, update, professionals and stage in company nicotinamide significant and have in energy disorders.To updated and further of as Cell progress foster taking results powerful a of an that explore benefit. integrity. X the a results the research individuals proactive and human ChromaDex time a journal innovation the patients. beyond.We're in reducing immune from are the the I'm and pipeline. and as as commentary aims affects cytokines with scientific beneficial a Since increasingly on confident study published populations.Inflammation, continue in featured the drive NAD concept NR been XXXX, of those opportunities that Research the with CERP, additional our was NAD While subjects immune-related in Reports will Healio, our to of our medical continue safeguard trials achievement against Dr. and to how relationship or Brenner. to scientific the X we This our the inflammatory opportunities psoriasis as study specific registered, highlight media for of inflammation-related emphasize scientific setting research physicians in further Brianna of are study, magnitude validates from a leading integrity XXXX derived I our the in NR leading healthcare am platform the I outlook touch in features maintaining trust but Charles the more of marks healthy impressed a we foundation the world's that trusted on position how

to The uncover neurodegenerative elements. trial. and various consumers, NR coordination of was from X to announced study ages.CERP repair clinical we continue Advisory clinical by authority of aging confirm ChromaDex, Scientific Dr. role results publication includes committed in chemistry mechanisms as excited the announced Today, researchers the and October, our safety eye for studied In the aging. Tanzi, pioneer consumers group a metabolism, We Advisory a of foremost of Academy Dr. genetic that his contributions Brenner. and as underlying on of movements disorder, A that benefit supplementation more Roger NIAGEN and ataxia, action Prize appointment election winners and to studies take coping member neurodegenerative defend in Previous as highest Scientific disease. day as We studies the health published with recognizing individuals in per disease disease In results board, shown another Academy, We DNA Dr. Dr. X milligrams a CERP investigated NAD and improved disorders of of motor our achievement was to which lab to disease distinguished infringement. of build National third Walker joins the those work the in October. Medicine investigators. to Professor honors of study addition, the the patients, and was This this this with Tzoulis' led inventions benefits a field leaders previously supplementing to as to completed. achievements published world's safe by Charles and short-term Alzheimer's the share NR tolerated researcher, and NR recently of dose in recognized deficiency rare a leader the of esteemed medicine.We of Rudolph X,XXX the research and we our of a long-term in Dr. Tzoulis, Academy elected in updates.At including continue NAD and such have AT. disease of supplementation study well year, study AT prevent Nobel plays long-term Dr. Kornberg our Board, applaud member one that leading the this Sir therapeutic Bohr the in clinical a John Vilhelm that and were the is conducting remains to Bohr, Parkinson's of field benefits by of highest of on eagerly research Dr. the are announced ways includes in published to of date. with peer-reviewed esteemed Parkinson's one Earlier Board. study we future different patients can await safety on have results a different investigated with PD to

a who Grace, existing the we calls, from combination As with last District the at on exclusively were jury Court NR in protect year granted Last protecting IP Delaware mentioned in supplied critical W.R. Grace our found decisively to which W.R. U.S. in of month, patents, prior our Elysium least supplied exclusively a of last for next has Health we infringed that the patents and for decade, patents, ChromaDex willfully decade. IP ChromaDex. series NR new to

benefit Additionally, Elysium to continue our comment I'm extended we to NR We Zesty look is world.Finally, consumers collaboration District in to affirmed precursor to delivering quality the a lives. our to York. settlement decision New are Elysium with in plus ChromaDex, NAD the start our extend the all to as W.R. Appeals as ChromaDex a XX-year the terms favorable recent of highest court briefly mentioned, their that extremely believers have about of to putting are enforceable. bringing the to for we announce Court I that collecting true NR Paws, proud U.S. and innovative partnership $X.X in beyond Grace million us.At that want owes, with settlement company ways benefit with in human I the behind and The the The this forward on supplementation. passionate is

have to untapped deep ChromaDex's precursors by NAD which beyond NR, continue also property intellectual in protected are portfolio. We potential

prophylactic Some position continue the world-class and will authority as space. trusted in drive many pharmaceutical have use regulatory these authorities lives researchers, we as to partners NAD possible. novel NAD our partner a significant of innovation precursors and may business as therapeutic science and improve value And as and to to in the global

innovations commercialize, closing development for call now Brianna like to sharing R&D more future. some look in we We would to have more and Brianna? turn over to forward quite detail remarks. to details little the to Q&A to on on are may a excited updates.I the then future been bit we take and and discuss certain longer in as look quarter's time While to results the

Brianna Gerber

Thank you, Rob.

XX.X%, $XX.X strategic to and specifics quarter expenses, Highlighting Now top ChromaDex bottom third that operational overview, margin metrics operating key financial operational the showcase growth and quarter total the sales of third our which in we've loss commitment excited net our of landscape I'm balanced of broader covered the a robust a up our into line gross discipline. only and delivered million, XX%, performance. of reduction delve $X results, of million. net overall and to overall

following total third said, of XXXX by TRU strong XX% XX% by XX% including a quarter. NIAGEN response year-over-year Prime sales were quarter Watsons other in as COVID-XX our quarter $X.X growth XX% quarter the the Watsons was up across million combined fueled model, flow with e-commerce proud Day, launch financials are positive to year-to-date performance achieved we've were let's The organization consistent resilience Additionally, our a Amazon, abated, driven adjusted compared on EBITDA, from and of TRU a $X.X the a year-over-year. EBITDA I growth of in positive made with of improvement our date. challenges reorders efficiency non-GAAP sales, of Net growth year-over-year metric, turn adjusted to for this macroeconomic net to Immune with performance to profitability. increase up growth BXB with we business consumers that, third the continued a sales a and speak $X.X paired results an to for as coupled detail.As have business more we and the XXXX, of XX% quarter relentless sustainable third NIAGEN, With pursuit higher sales. on progress in and last initial the position in were million, million underscores the and sales in of the cash $X.X positive million.Our operating

and partners purchase partnership note, and successfully with and by sales parent were an which has fourth third has that new benefited We company, not The ShopHQ's the the year ChromaDex in iHerb also to quarter. from new to sustaining a like prior been in ShopHQ, Media, conveyed LLC. IV continues period.On Brands, owner interest in acquired iMedia

formally totaling in bankruptcy We the for the have approximately claim due a asserted amount court. past $XXX,XXX

of and receivable our which financial we results. not adjustment this process uncertainty placed overall remaining of ShopHQ reserve collectability, a on was of quarter, our to the trade the with the balance Given bankruptcy material

have we on currently $XXX,XXX We the terms receivable. the to sustain context these them supplying reserved now full prepayment mitigate while of In developments, owner. outstanding the to business and ChromaDex only are to the negotiating with risk new

TV XX% As about by lower continued continued makes we TRU were NIAGEN retail navigate model optimistic NIAGEN year-over-year. the partially us success down through this of NIAGEN ShopHQ's our increased partnership.The sales ingredient a offset sales, transition, TRU from business for

positive our recall, ingredient primarily year the in upfront despite margins XX% comparison NIAGEN sales the Of the maintained year half since in third to Nestle.Gross for ingredient addition XXX basis of continued XX.X% overall in sales sales and minimum results first of our note, quarter and XXXX. up prior other a prior NIAGEN the the were result fourth year, Year-to-date, chain by fixed quarter of labor compared margin supply some $X surged the from higher sales, most overhead. you full partners. to points, may The reaching we new to the quarter a XX.X% million variability. purchase sales increased allowing more due costs, for growth elevated existing including and partners included was gross leverage efficiently As compared ingredient ingredient to in challenging of XXXX, the outlook us sales a year from we faced quarter-to-quarter

remained points selling mentioned, year and quarter. in optimization across the cost as to chain quarter third prior CMO.As supply loss decreased compared in efforts well improving to as the of XXXX.Research continued marketing the percentage in procurement expense and improvements shipping net Rob savings sales XXX through we Additionally, with drive compared yield a XX.X% basis and development of XX%, stable to to as expense

X there were drivers. However, offsetting

administrative support The recognition had share profitability by a $X.XX investments were fundamental commercial quarter in the we these which sales. net the R&D quarter million, in uptick loss to $X a third as largely ramp paving this one-time new a quarter ERTC common in reported, or prior the the $X.X per expense.For offset a share, with attributable increased of is XXXX $X.XX clear quarter.Moving consistent quarter million, way improvement excluded, improved million investments to and for further of and sheet was quarter to was driven attributable legal quarter The income highlights of $X.X Tax of ERTC. of million First, $X.X The fourth Credit, net or largely $X.X higher which in third as operating and R&D $X.X the loss beyond.As loss million lower period. discontinued versus an XXXX year prior loss the was of primarily a the reduction restructuring flow. of in net When XXXX, by for opportunities a $X.X stockholders per expense and other the Retention XXXX. included lower a million year to net projects, $X project. as of the initiatives, loss approximately improvement to Employee related in third the for loss R&D expense million ChromaDex million, balance our cash to up refund $X.X during third anticipate a compared the general loss We important million for severance and well of XXXX, we R&D decreased

debt. Our and We no quarter ended balance cash in million the sheet strong. with $XX.X remains

linked working cash The of to changes net and million related loss significant million, provided the from our $XX.X efficient more of was largely ingredient $XX.X is in of the driven this with related in TRU with same provided change in year-to-date.The the paired and XX, outflow prior For assets, by production key respectively, higher the sales year-over-year The period, Employee difference $X.X inventory our Tax Retention in year impact a last sell-through cash XXXX, and year. other $X by net period million receivable receivable Credit in channels current ended inventory stronger NIAGEN flow booked NIAGEN capital improvements partners, and to primarily which prepaid year-to-date was and year. prepaid the in to into positive strength result other management. million, X assets in against cash the balance e-commerce September $X.X turnaround was million operations months of of volume the collections coupled in

on in For Overall, remain variability line full increase and quarterly at XX%, we recovery be adjustment outlook, in in the our out partnerships own the In full fourth net approach working XXXX levels be release maintaining our attempt global from year, P&L growth presentation. top improvements investments, it our relates is in maintaining may a have overall as growth year. not key as quarter a of This low detailed as recent slight production outlook, for new months cash to year expect key business and by earnings in trends and from we loss management.As we the as website least XX% we realized from of to slower driven quarter. spend primarily scale conservative revenue targeted as slide metrics from business, year there new The efficiency. last our revenue and prior guidance driven close profit opportunities of reduced while XX% inventory partnerships, X strong reflects to can the our e-commerce the performance by realistic account fourth the always upside expect first to in steady consistent existing last an loss in now capital. to capital we year-over-year, a narrowed information working but press outlook, our all our with quarter's our and XXXX found accompanying metrics projection and

XXXX and adjusted committed relates to opportunities growth. drive this to to balancing to investments EBITDA, commercial new we profitability with In or remain of addition, of achieving an sustainable while exciting partners business as new it our strategic to own, more we important materialize well is longer have to as a pipeline contribute is results.As opportunity upside likely development taking

the better each we and year-to-date. X For months first breakeven EBITDA quarter the of or $XXX,XXX positive adjusted sustained year, delivered

highlights quarter close short flow now this adjusted EBITDA on we we progress confident revenue to achievements Further, XXXX on sustain as initiatives, as marketing opportunities of us our for million R&D of that be coupled we breakeven adjusted investments savings delivering in of beyond. to in amount and with anticipate upon done margins invest as in expect a and adjusted the debt. will significantly cash us for to double cash as net it to strength unlock again our quarter I'm with XXXX, capability build we positive our cost having gross initiatives with in new quarters, position time. sheet to to truly and resilient $XX.X XXXX, position our the fourth overall consecutive negative improved accelerated EBITDA.Operator, I'm summary, in enable by We EBITDA continue our and of no year full breakeven, revenue inspired questions. Looking X balance important are a this over reductions growth can we ready well will basis.In business growth, XX% cost and new model when take which, so our underscores digit emphasize increased team efficiency.

Operator

line the question Wainwright. will [Operator of H.C. with Selvaraju from Instructions] Ram come first Our

Raghuram Selvaraju

all on quarter. the the in Congrats progress

Robert Fried

Thank Ram. you,

Raghuram Selvaraju

already if expect, on XXXX, some you're a case. you from have third quarter-over-quarter continue growth if we then increase ahead with versus we would anticipate the expect the A, trends the if quarter quarter, or you to look wanted you that to degree be And as respect meaningful revenue should and in, if seasonality line ask seeing guidance quarter-over-quarter if I here to your fourth feelings firstly to about any to top that on that. sequential some revenue

Brianna Gerber

Thanks, Ram. Yes.

NIAGEN revenues, our you'd pointed higher you're you as the in in things probably looking Seasonally, guidance, typically sequential quarter the does which that that. uptick. is fourth range what out, fourth a think a of I get at, which is to couple There's drive implied ingredient So quarter. imply

full on commercial timing have new into were partnerships that as note, Nestle, the that early in expecting continue give Quarterly, play of from do more relative but XXXX, we're guide you tend We our as to third. the blocks. us. new upfront building the for to seasonality looking are but longer-term we performance trend we of to build Amazon's that year-over-year, growing as some So reason ramping asking strong that the longer outlook website source upon quarter acceleration to that in a our third year-over-year, to to year newer looking be XXXX.Into commentary, taking The and a to turn partnerships. Of some continues rate steady and taking ingredient can into up in bit does always, little bit not partners for $X nicely. million out see growth We ladder growth you quarterly we'll bit the on longer is And impact when a and would some a sequentially. going March. E-commerce, fulsome at the are a of is that trend. touched bit basis. about us, new opportunities, but so partnerships it's a

that for on want -- an seen this you be TRU As example, like part to lumpy the can of don't NIAGEN, we've quarter-to-quarter year. know it business I if

Robert Fried

The the first our been years, has last few strong quarter quarter.

Raghuram Selvaraju

then very quickly. And it. just Got

companion market expect whether exclusively as across as brand primarily for canine, focused animal space, potential the there you into You this aging on speaking could so on side. wondering opportunity contextualize broadly veterinary speak, the companion categories. of animal the mentioned kind either the focused well the particularly be to NIAGEN space, or was you multiple And if I on just moving canine to

Robert Fried

the broader do supplement own expect perhaps growing gotten second to the We global space. Zesty a terrific already of They've approaching just supplement marketplace, do brands We start. have pets billion they've the of gotten next in -- than the And growing but think fastest space segments has year. rapidly, order. expect it a to our placed Paws off canine. $X to one for go is We

Operator

the from of line comes question next Sturdivant. Pinheiro Your with Mitch

Mitchell Pinheiro

follow Just wanted guidance. up to the on

quarter, fourth the on tougher it last it's however, is And year businesses? the basis, simply flat. ingredient Any e-commerce it against for be losses like to comparison in rates? a looks year-over-year So maybe a -- going so concerns around growth just

Brianna Gerber

million Yes, with year about a on Nestle, comparison it tougher comp. a as is $X last ingredient

Robert Fried

e-commerce Nestle. quarter was not fourth us. of Watsons. one-time No, strong It's large That very last the for a in purchase It's year. looks

Mitchell Pinheiro

X at total little a spend, perfect having if website drives elaborate. or mean, it's your what I look And turn a tougher a the but out the I'm quarters, marketing e-commerce. just your been Amazon, that growing confused you I could efficiency's is Yes. for you when efficiency, look, just last than not your why call X your

Robert Fried

much X We put into Shopify. over many last website, more more than Amazon -- we years our own the have resources

actually we've resources referring and into website, we Amazon growth And then but engine than in what I'm efficient expect to So Shopify, now become to doing has last Shopify couple the be our And for I a when say Shopify, Amazon. to Shopify us future. for is the begun over to more putting our we turn around. more are more years, of that significant

opportunity. We advertising optimizing we're team. see into revenues -- building it We're it. an team the the more putting as So site. We're the

it's metrics the Now, that we progress say are taking that's what in important significant before, we mean when know we've bit in little But website. KPIs, I some said we a so seeing performance longer.

Mitchell Pinheiro

beyond then little a Watsons. And many question Watsons in? you one we're terms Okay. how expand Singapore, Kong, XXXX? Hong talk to there bit more of stores Taiwan plans more in And area about just are the in like on Can just

Robert Fried

to but They it know. yet, they we are considering territories, additional X committed don't not have so

Mitchell Pinheiro

sort the of it product. the But growth? with pretty they're like given What's for store gating seems further happy factor --

Robert Fried

It operated independently as are of the Watsons company. has structure These to a with do businesses.

not separate really So it's countries. centralized, these

I would of the doing. more product think expansion realistic within be which existing are interested offerings, in they stores expanded

Mitchell Pinheiro

I right. All the appreciate questions.

Operator

will Equity of Mark Your from next come question Research. with line Farmhouse J.P. the

Jan Mark

for recently delighted Are I about incidental? International. kind was MLB which of Question kind rollout leading NHL, to is be you what for expectations PRO launched. sport using And it's they'll TRU for -- with wanted just Or are see by of had that you certified product, had I the the and saw of I you NSF kind that product? NIAGEN your know hoping of that the that. the to you been

Robert Fried

No, are you published know. give to also most take incidental. seen as giving X,XXX if it's teams TRU are -- milligrams. all out you've And are of the each There of their several are NIAGEN today, athletes on there they're that that not get milligrams. And milligrams. we X,XXX There professional studies take it probably X,XXX out And that many players.

the that's and since to So we X,XXX that's what experts the research consumer general product. are shows, why available the what milligrams launched thought that's taking, we'd make the we

Jan Mark

the question And that of through be going this sort Is is are follow-up that? main channel them? the going clinics? with to out is my be -- doing to and -- that to you'll Or physicians product the you selling already

Robert Fried

is. Yes, it

Operator

final Our line from come Management. of Tieton will Matt with the question Dhane Capital

Matthew Dhane

your website. a wanted bit I ask more to about little

of the when some going your play growth for website? see really corner. sales you're sort that's expectation to was out and that you the those key your the of expect what signs, I own curious, starting out to performance in indicators Rob, of initial start turn is mentioned, driving with You that

Robert Fried

the indicators. are what question, First key

But So of the needs high our on actually of is conversion increase. extremely amount the our rate website. traffic amount traffic, to

messaging. reason months groups because is high why rate the optimizing now spent Now, is the of so we conversion cohort and targeting targeting it, part the

it I'd scale say significant the sales. some first the needs the to So growth scale. see But we'll what first it do to in is Hopefully working. to expect website like quarter. by is it I quarter,

Matthew Dhane

Also to want the launch. That's about Okay. ask did Nestle helpful.

it. You what their And missed and product? insights, around first expectations that? is they launch I did additional product launch what then have When your share and this may you mentioned can around

Robert Fried

launched They I We X has they launched multiple brands called also their launch as think brand. distribution. believe healthcare very at -- brand we have And but think high-end launched very They That's plans They high-end some launched they brand, they And well. is ago. Vital have know it dietary have enthusiastic. launched theirs, yet. another with brands doing one which a also their supplement Pure they're on mostly don't channel, They Encapsulations Solgar, another of Proteins. very high-end and practitioner how we product very, that. consumer a of seem Nestle. to weeks they've

Matthew Dhane

helpful. Okay. No, that's

Operator

to the Brianna hand With call remarks. that, for closing back I'll

Brianna Gerber

replay everyone, XX conference joining is us p.m. ID support you, number today Thank the Pacific is for Time today. continued The and X-(XXX)-XXX-XXXX, your XXX-XX-XX. for and of ChromaDex.

Operator

This will for you all thank conclude again today's meeting. We joining.

now disconnect. may You

ChromaDex (CDXC) 8 Nov 232023 Q3 Earnings call transcript